Skip to main content
Home
Issues
Issue Archive
Topics
Conference Correspondent
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
Issue Archive
Topics
Conference Correspondent
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Select Drug Profiles
Orphan Drug Expenditures in the United States Expected to Stabilize
Wayne Kuznar
Read More
Economic Value of Survival Gains for MDS Could Exceed $100 Billion
Chase Doyle
Read More
Once Off Patent, Imatinib Will Be the Most Cost-Effective Treatment for Newly Diagnosed CML
Wayne Kuznar
Read More
High Cancer Drug Prices Hurt Patients
Read More
Stem-Cell Mobilization More Cost-Effective with Plerixafor
Kate Smith
Read More
Financial Toxicity Impacts Treatment Adherence
Kate Smith
Read More
American-Style Capitalism Drives Drug Development: Cancer Therapies Targeting Small Subpopulations Dictate Prices
Kate Smith
Read More
FDA Approvals
The Hematology Pipeline Is Abundant
Wayne Kuznar
,
Kate Smith
Read More
Value and Cost-Effectiveness Analyses Should Be Included in Reimbursement Decisions
Kate Smith
Read More
Leukemia
,
Oncology
Psychological Distress and Financial Burden Impact Adherence to CML Treatment
Phoebe Starr
Read More
132
133
134
135
136
137
138
Page 135 of 244
Results 1341 - 1350 of 2438
